See more : Bakhu Holdings, Corp. (BKUH) Income Statement Analysis – Financial Results
Complete financial analysis of ImmunityBio, Inc. (IBRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmunityBio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- SBI Sumishin Net Bank, Ltd. (7163.T) Income Statement Analysis – Financial Results
- Cognetivity Neurosciences Ltd. (CGNSF) Income Statement Analysis – Financial Results
- Mirrabooka Investments Limited (MIR.AX) Income Statement Analysis – Financial Results
- Uranium Royalty Corp. (UROY) Income Statement Analysis – Financial Results
- Tattooed Chef, Inc. (TTCF) Income Statement Analysis – Financial Results
ImmunityBio, Inc. (IBRX)
About ImmunityBio, Inc.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 622.00K | 240.00K | 934.00K | 605.00K | 2.20M | 47.00K | 45.00K | 44.00K | 236.00K | 641.00K | 600.00K |
| Cost of Revenue | 0.00 | 24.19M | 0.00 | 9.15M | 9.01M | -3.11M | 0.00 | 0.00 | 0.00 | 0.00 | 253.00K |
| Gross Profit | 622.00K | -23.95M | 934.00K | -8.54M | -6.81M | 3.16M | 45.00K | 44.00K | 236.00K | 641.00K | 347.00K |
| Gross Profit Ratio | 100.00% | -9,980.00% | 100.00% | -1,411.90% | -309.26% | 6,717.02% | 100.00% | 100.00% | 100.00% | 100.00% | 57.83% |
| Research & Development | 232.37M | 248.15M | 195.96M | 139.51M | 112.00M | 53.42M | 39.78M | 26.55M | 11.43M | 1.60M | 446.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.39M | 57.12M | 95.39M | 227.68M | 4.33M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.07M | -3.30M | -1.00M | -1.47M | 0.00 | 0.00 |
| SG&A | 129.62M | 102.71M | 135.26M | 71.32M | 46.46M | 35.46M | 53.82M | 94.39M | 226.21M | 4.33M | 2.42M |
| Other Expenses | 886.00K | -736.00K | 193.00K | 1.49M | -534.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 362.87M | 350.86M | 331.21M | 210.83M | 158.45M | 88.88M | 93.60M | 120.94M | 237.64M | 5.92M | 2.87M |
| Cost & Expenses | 362.87M | 350.86M | 331.21M | 210.83M | 158.45M | 98.44M | 99.17M | 124.54M | 239.11M | 6.24M | 2.87M |
| Interest Income | 863.00K | 2.71M | 836.00K | 1.73M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K |
| Interest Expense | 129.20M | 63.52M | 14.85M | 9.07M | 5.92M | 433.00K | 618.00K | 66.00K | 0.00 | 0.00 | 463.00K |
| Depreciation & Amortization | 18.51M | 24.19M | 19.12M | 9.15M | 9.01M | 9.56M | 5.57M | 3.61M | 1.47M | 128.00K | 4.00K |
| EBITDA | -436.18M | -335.51M | -315.38M | -187.93M | -142.27M | -86.74M | -90.73M | -117.71M | -235.71M | -5.68M | -1.58M |
| EBITDA Ratio | -70,125.72% | -143,324.17% | -33,865.52% | -32,252.56% | -6,356.77% | -189,008.51% | -207,897.78% | -274,756.82% | -100,594.92% | -949.14% | -263.17% |
| Operating Income | -362.25M | -351.30M | -330.28M | -220.88M | -156.25M | -98.39M | -99.12M | -124.50M | -238.88M | -6.21M | -2.27M |
| Operating Income Ratio | -58,239.55% | -146,374.17% | -35,361.88% | -36,509.09% | -7,095.87% | -209,338.30% | -220,266.67% | -282,954.55% | -101,218.64% | -969.11% | -378.17% |
| Total Other Income/Expenses | -221.64M | -65.99M | -19.56M | -25.36M | -3.95M | 1.66M | 2.20M | 3.12M | 1.70M | -609.00K | 223.00K |
| Income Before Tax | -583.89M | -417.29M | -349.84M | -226.03M | -160.26M | -96.73M | -96.92M | -121.38M | -237.18M | -6.21M | -2.05M |
| Income Before Tax Ratio | -93,873.31% | -173,869.17% | -37,456.00% | -37,360.83% | -7,278.07% | -205,806.38% | -215,368.89% | -275,865.91% | -100,498.73% | -969.11% | -341.00% |
| Income Tax Expense | -40.00K | 34.00K | 9.00K | -1.85M | -105.00K | -503.00K | -493.00K | -572.00K | -301.00K | 1.00K | 1.00K |
| Net Income | -583.20M | -417.32M | -349.85M | -224.19M | -160.16M | -96.23M | -96.42M | -120.81M | -236.88M | -6.21M | -2.05M |
| Net Income Ratio | -93,761.41% | -173,883.33% | -37,456.96% | -37,055.70% | -7,273.30% | -204,736.17% | -214,273.33% | -274,565.91% | -100,371.19% | -969.27% | -341.17% |
| EPS | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 | -1.20 | -1.47 | -3.31 | -0.02 | -2.57 |
| EPS Diluted | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 | -1.20 | -1.47 | -3.31 | -0.02 | -2.57 |
| Weighted Avg Shares Out | 508.64M | 399.90M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
| Weighted Avg Shares Out (Dil) | 508.64M | 399.90M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
IBRX FINAL DEADLINE TUESDAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important August 29 Deadline in Securities Class Action - IBRX
NEW YORK , Aug. 23, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and May 10, 2023, both dates inclusive (the "Class Period"),...
FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $750,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 23, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of §§10(b) and...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ImmunityBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 29, 2023 - (NASDAQ: IBRX)
NEW YORK , Aug. 22, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc.. Shareholders who purchased shares of IBRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff...
IMPORTANT AUGUST DEADLINE: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $500,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b)...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 20, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ: IBRX) for violations of §§10(b)...
FINAL DEADLINE THIS MONTH: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of §§10(b) and...
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit
BENSALEM, Pa. , Aug. 18, 2023 /PRNewswire/ -- Law Offices of Howard G.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ImmunityBio, Inc. of Class Action Lawsuit and Upcoming Deadline - IBRX
NEW YORK , Aug. 18, 2023 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX), and certain officers. The class action, filed in the United States District...
IBRX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving ImmunityBio, Inc.
NEW YORK, NY / ACCESSWIRE / August 18, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased ImmunityBio, Inc. ("ImmunityBio") (NASDAQ:IBRX) between May 23, 2022...
IBRX LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving ImmunityBio, Inc.
NEW YORK, NY / ACCESSWIRE / August 18, 2023 / The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased ImmunityBio, Inc. ("ImmunityBio") (NASDAQ:IBRX) between May 23, 2022...
Source: https://incomestatements.info
Category: Stock Reports